Dhanuka Lab implements resolution plan for debt-ridden Orchid Pharma

The resolution plan will fetch the secured lenders around 32.3% recovery

Orchid Pharma

The secured lenders will also receive around 4,08,164 equity shares at an issue price of Rs 10 each for part of their debt

The resolution plan of Gurgaon-based Dhanuka Laboratories for the revival of Chennai-based debt-ridden Orchid Pharma Ltd has been implemented, potentially fetching secured lenders around 32.3 per cent recovery. In addition,

Also Read

SC sets aside NCLAT order on Dhanuka's resolution plan for Orchid Pharma

Accord Group enters pharma business, targets sales in 18 states

NCLAT stays NCLT ban on ex-bankers' appointment as resolution professionals

Systemic change: Hits and misses of India's bankruptcy reforms code

Essar Steel verdict: Strengthening committee of creditors comes with riders

Auto dealers fear huge losses with BS-IV inventory stuck in Covid-19 jam

Hit by Covid-19 lockdown, start-ups and SMEs seek slew of sops from Govt

Coronavirus: ArcelorMittal working on 3D printed ventilator prototype

Natural gas prices cut by steep 26%, makes huge dent in ONGC revenues

Coronavirus: ITC repurposes Himachal perfume plant to produce sanitisers

First Published: Mar 31 2020 | 8:25 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to